A Clinical trial to study the effect of Bilva Patra And Laghu Pancamula In the patients having sign and symptoms of Shotha (Inflammation)â??

â??Nidanatmaka, Prayogika And Upasayatmaka Studies To Evaluate The Efficacy Of Bilva Patra And Laghu Pancamula In Shotha (Inflammation)â??

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011984

Enrollment

Registered

2018-02-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Shotha ( Inflammation)

Interventions

Intervention1: Bilva patra kwatha: 20 ml BD for 30 days before meal. Control Intervention1: Laghu panchamula kwatha: 20 ml BD for 30 days before meal.

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patient is willing to fill consent form. 2 Clinical signs and symptoms of inflammation. 3 Oedema due to trauma, injury. 4 Oedema due to insect bite or infection.

Exclusion criteria

Exclusion criteria: 1 Patient not willing for trial. 2 Oedema due to pregnancy. 3 Asadhya Laksana and Updrava as mentioned in texts. 4 Oedema due to burn. 5 Oedema due to systemic pathology like cardiac, renal diseases.

Design outcomes

Primary

Measure	Time frame
patients of both sexes between age group 18 to 60 of shotha will be selected for relieving sign and symptoms.Timepoint: patients of both sexes between age group 18 to 60 of shotha will be selected for relieving sign and symptoms after 4 weeks.	—

Secondary

Measure	Time frame
Asses the comparative efficacy between Bilva Patra and Laghu Panchmula Kwath after 4 weeks in case of Shotha.Timepoint: Asses the comparative efficacy between Bilva Patra and Laghu Panchmula Kwath after 4 weeks in case of Shotha.	—

Countries

India

Contacts

Public ContactDr Ritisha Verma

National Institute of Ayurveda

gpawankumar@rediffmail.com9314502834

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026